应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06185 康希诺生物
未开盘 05-24 16:08:28
22.050
-0.650
-2.86%
最高
22.650
最低
21.800
成交量
211.74万
今开
22.550
昨收
22.700
日振幅
3.74%
总市值
54.56亿
流通市值
29.25亿
总股本
2.47亿
成交额
4,710万
换手率
1.60%
流通股本
1.33亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
智通AH统计|5月24日
智通财经 · 05-24 16:15
智通AH统计|5月24日
康希诺获融资买入0.20亿元,近三日累计买入0.28亿元
金融界 · 05-24 08:21
康希诺获融资买入0.20亿元,近三日累计买入0.28亿元
康希诺生物逆市涨超9% 疫苗股再度引关注公司在研管线丰富
新浪港股 · 05-23
康希诺生物逆市涨超9% 疫苗股再度引关注公司在研管线丰富
港股异动 | 康希诺生物(06185)涨超9% 疫苗股再度引关注 公司在研管线丰富
智通财经 · 05-23
港股异动 | 康希诺生物(06185)涨超9% 疫苗股再度引关注 公司在研管线丰富
康希诺生物盘中异动 急速拉升5.15%报22.450港元
自选股智能写手 · 05-23
康希诺生物盘中异动 急速拉升5.15%报22.450港元
康希诺生物(06185)上涨5.15%,报22.45元/股
金融界 · 05-23
康希诺生物(06185)上涨5.15%,报22.45元/股
港股概念追踪 |美国确认第二例人感染禽流感病例 疫苗板块受关注(附概念股)
智通财经 · 05-23
港股概念追踪 |美国确认第二例人感染禽流感病例 疫苗板块受关注(附概念股)
康希诺生物(06185)向渤海银行购买1.6亿元的结构性存款
智通财经 · 05-21
康希诺生物(06185)向渤海银行购买1.6亿元的结构性存款
康希诺生物(06185.HK)购买1.6亿人币结构性存款
阿斯达克财经 · 05-21
康希诺生物(06185.HK)购买1.6亿人币结构性存款
康希诺生物(06185)下跌5.05%,报20.7元/股
金融界 · 05-21
康希诺生物(06185)下跌5.05%,报20.7元/股
港股概念追踪 |新冠变异株正蔓延 国家疾控局:新冠变异株KP.2引发新一次感染高峰的可能性低(附概念股)
智通财经 · 05-16
港股概念追踪 |新冠变异株正蔓延 国家疾控局:新冠变异株KP.2引发新一次感染高峰的可能性低(附概念股)
康希诺生物(06185)上涨5.13%,报21.5元/股
金融界 · 05-14
康希诺生物(06185)上涨5.13%,报21.5元/股
康希诺生物(06185)股价上升5.134%,现价港币$21.5
阿斯达克财经 · 05-14
康希诺生物(06185)股价上升5.134%,现价港币$21.5
北向资金5月13日净卖出康希诺9.94万股 连续3日减持
自选股智能写手 · 05-14
北向资金5月13日净卖出康希诺9.94万股 连续3日减持
康希诺:在研产品管线中的早期候选产品初步应用合成生物学相关技术
界面 · 05-13
康希诺:在研产品管线中的早期候选产品初步应用合成生物学相关技术
康希诺董秘回复: 公司已与Ocugen建立合作关系,合作项目包括OCU400,具体合作信息涉及商业机密
证券之星 · 05-13
康希诺董秘回复: 公司已与Ocugen建立合作关系,合作项目包括OCU400,具体合作信息涉及商业机密
港股异动 | 康希诺生物(06185)盘中涨超6% 瑞银称MCV4业务收入今年或增长50%
智通财经 · 05-09
港股异动 | 康希诺生物(06185)盘中涨超6% 瑞银称MCV4业务收入今年或增长50%
康希诺一季度亏损近2亿元 销售费用占营收比例41%高于同行
中国网财经 · 05-09
康希诺一季度亏损近2亿元 销售费用占营收比例41%高于同行
康希诺生物(06185)上涨5.25%,报21.05元/股
金融界 · 05-09
康希诺生物(06185)上涨5.25%,报21.05元/股
康希诺生物盘中异动 快速拉升5.00%
自选股智能写手 · 05-09
康希诺生物盘中异动 快速拉升5.00%
暂无数据
公司概况
公司名称:
康希诺生物
所属市场:
SEHK
上市日期:
--
主营业务:
康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。
发行价格:
--
{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":22.05,"timestamp":1716538108033,"preClose":22.7,"halted":0,"volume":2117400,"delay":0,"floatShares":132670900,"shares":247449899,"eps":-6.4651136,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.65,"latestTime":"05-24 16:08:28","open":22.55,"high":22.65,"low":21.8,"amount":47095634,"amplitude":0.037445,"askPrice":22.1,"askSize":4200,"bidPrice":22.05,"bidSize":22400,"shortable":3,"etf":0,"ttmEps":-6.586995733404159,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716773400000},"adr":0,"listingDate":1553702400000,"adjPreClose":22.7,"dividendRate":0.040956,"openAndCloseTimeList":[[1716514200000,1716523200000],[1716526800000,1716537600000]],"volumeRatio":0.8044208727816291,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":51.15,"timestamp":1716534000000,"preClose":53.94,"halted":0,"volume":2317048,"delay":0,"premium":"-59.93"}},"requestUrl":"/m/hq/s/06185/tweets","defaultTab":"tweets","newsList":[{"id":"2437070479","title":"智通AH统计|5月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2437070479","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437070479?lang=zh_cn&edition=full","pubTime":"2024-05-24 16:15","pubTimestamp":1716538504,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止5月24日收盘,东北电气、弘业期货、浙江世宝分列AH溢价率前三位,溢价率分别为1127.27%、705.26%、559.17%;招商银行、比亚迪股份、紫金矿业分列AH溢价率末三位,溢价率分别为14.79%、20.53%、22.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1125704.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437415747","title":"康希诺获融资买入0.20亿元,近三日累计买入0.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437415747","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2437415747?lang=zh_cn&edition=full","pubTime":"2024-05-24 08:21","pubTimestamp":1716510109,"startTime":"0","endTime":"0","summary":"5月23日,沪深两融数据显示,康希诺获融资买入额0.20亿元,居两市第394位,当日融资偿还额0.15亿元,净买入484.69万元。最近三个交易日,21日-23日,康希诺分别获融资买入0.05亿元、0.03亿元、0.20亿元。融券方面,当日融券卖出0.65万股,净卖出0.25万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405240822109555caec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405240822109555caec&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437432275","title":"康希诺生物逆市涨超9% 疫苗股再度引关注公司在研管线丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2437432275","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2437432275?lang=zh_cn&edition=full","pubTime":"2024-05-23 10:14","pubTimestamp":1716430440,"startTime":"0","endTime":"0","summary":" 康希诺生物早盘逆市上涨9.37%,现报23.35港元,成交额5652.63万港元。 据悉,在研管线方面,康希诺生物13 价肺炎结合疫苗PCV13i 上市申请已获受理;婴幼儿组分百白破DTcP 已完成III 期受试者入组;吸附破伤风疫苗已启动III 期临床;重组带状疱疹疫苗已在加拿大启动I 期临床;重组脊髓灰质炎疫苗已在澳大利亚启动I 期临床。另外,公司与阿斯利康就mRNA 疫苗研发达成了合作开发协议。股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-23/doc-inawesep3801646.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-23/doc-inawesep3801646.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2437273735","title":"港股异动 | 康希诺生物(06185)涨超9% 疫苗股再度引关注 公司在研管线丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2437273735","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437273735?lang=zh_cn&edition=full","pubTime":"2024-05-23 09:56","pubTimestamp":1716429389,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,康希诺生物涨超9%,截至发稿,涨9.84%,报23.45港元,成交额4177.58万港元。受此影响,周三多只美股疫苗股大涨。据悉,在研管线方面,康希诺生物13 价肺炎结合疫苗PCV13i 上市申请已获受理;婴幼儿组分百白破DTcP 已完成III 期受试者入组;吸附破伤风疫苗已启动III 期临床;重组带状疱疹疫苗已在加拿大启动I 期临床;重组脊髓灰质炎疫苗已在澳大利亚启动I 期临床。另外,公司与阿斯利康就mRNA 疫苗研发达成了合作开发协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1124922.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437727808","title":"康希诺生物盘中异动 急速拉升5.15%报22.450港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437727808","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2437727808?lang=zh_cn&edition=full","pubTime":"2024-05-23 09:45","pubTimestamp":1716428712,"startTime":"0","endTime":"0","summary":"2024年05月23日早盘09时45分,康希诺生物股票出现波动,股价大幅上涨5.15%。截至发稿,该股报22.450港元/股,成交量55.82万股,换手率0.42%,振幅5.15%。资金方面,该股资金流入783.798万港元,流出238.917万港元。机构评级方面,在所有6家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。康希诺生物股票所在的生物技术行业中,整体跌幅为0.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052309451287e8925d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052309451287e8925d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437785312","title":"康希诺生物(06185)上涨5.15%,报22.45元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2437785312","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2437785312?lang=zh_cn&edition=full","pubTime":"2024-05-23 09:45","pubTimestamp":1716428709,"startTime":"0","endTime":"0","summary":"5月23日,康希诺生物(06185)盘中上涨5.15%,截至09:45,报22.45元/股,成交1226.29万元。康希诺生物股份公司是一家专注于疫苗研发、生产和商业化的高科技生物制品企业,其主要产品包括新冠疫苗、四价流脑结合疫苗、二价流脑结合疫苗和重组埃博拉病毒病疫苗等。公司已在香港和上海两地上市,拥有全球创新的五大技术平台,已建立数十条产品研发管线,并在中国天津、上海以及墨西哥、巴基斯坦、马来西亚等国家建立了大规模现代化疫苗产业基地。截至2024年一季报,康希诺生物营业总收入1.14亿元、净利润-1.7亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/23094540746461.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2437222725","title":"港股概念追踪 |美国确认第二例人感染禽流感病例 疫苗板块受关注(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2437222725","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437222725?lang=zh_cn&edition=full","pubTime":"2024-05-23 09:23","pubTimestamp":1716427432,"startTime":"0","endTime":"0","summary":"当地时间5月22日,根据当地卫生官员报告,美国密歇根州已经确认该州第二例人感染禽流感的病例,感染者为一名农场工人,有轻微症状、感染后很快恢复。据悉,这已经是全美今年报告的第三例禽流感病例,上个月,美国南部得克萨斯州一农场工人在接触病牛后出现红眼等症状,为全美今年首例禽流感病例。美国方面周三确认了第二例人感染禽流感病例,受此影响,疫苗概念股全线走高。市场消息:Moderna和辉瑞与美国就H5N1禽流感疫苗进行讨论。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1124906.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437495960","title":"康希诺生物(06185)向渤海银行购买1.6亿元的结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2437495960","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437495960?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:31","pubTimestamp":1716280305,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康希诺生物(06185)公布,于2024年5月21日,公司与渤海银行订立渤海银行结构性存款协议VII,据此,公司同意向渤海银行购买本金金额人民币6000万元的结构性存款;及于2024年5月21日,公司与渤海银行订立渤海银行结构性存款协议VIII,据此,公司同意向渤海银行购买本金金额人民币1亿元的结构性存款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123829.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437057495","title":"康希诺生物(06185.HK)购买1.6亿人币结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2437057495","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2437057495?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:31","pubTimestamp":1716280260,"startTime":"0","endTime":"0","summary":"康希诺生物(06185.HK) 公布,今日(5月21日),与渤海银行订立两份结构性存款协议,涉资共1.6亿元人民币,年化固定收益率为1.6%,预期最高年化收益率为2.7%。存款期限分别至6月24日和8月26日。(ha/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-21 12:25。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230120154913053_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230120154913053_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1350996/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2437461390","title":"康希诺生物(06185)下跌5.05%,报20.7元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2437461390","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2437461390?lang=zh_cn&edition=full","pubTime":"2024-05-21 14:29","pubTimestamp":1716272954,"startTime":"0","endTime":"0","summary":"5月21日,康希诺生物(06185)盘中下跌5.05%,截至14:29,报20.7元/股,成交2004.34万元。康希诺生物股份公司是一家专注于疫苗研发、生产和商业化的高科技生物制品企业,其主要产品包括新冠疫苗、四价流脑结合疫苗、二价流脑结合疫苗和重组埃博拉病毒病疫苗等。公司已在香港和上海两地上市,拥有全球创新的五大技术平台,已建立数十条产品研发管线,并在中国天津、上海以及墨西哥、巴基斯坦、马来西亚等国家建立了大规模现代化疫苗产业基地。截至2024年一季报,康希诺生物营业总收入1.14亿元、净利润-1.7亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/21142940717787.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435131692","title":"港股概念追踪 |新冠变异株正蔓延 国家疾控局:新冠变异株KP.2引发新一次感染高峰的可能性低(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435131692","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435131692?lang=zh_cn&edition=full","pubTime":"2024-05-16 08:01","pubTimestamp":1715817707,"startTime":"0","endTime":"0","summary":"从全球范围来看,一种被命名为KP.2的新冠变异株正在蔓延。国家疾控局官方账号发布新冠病毒KP.2变异株健康科普问答,专家研判认为,当前KP.2亚分支感染病例在我国本土病例中的占比极低,短期内成为我国优势流行株的可能性低,引发新一次感染高峰的可能性低。据国家疾控局发布的消息,截至5月12日,在我国本土病例中共监测到25条KP.2序列。抗新冠创新药先诺欣纳入新版国家医保药品目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121794.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435531434","title":"康希诺生物(06185)上涨5.13%,报21.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435531434","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435531434?lang=zh_cn&edition=full","pubTime":"2024-05-14 10:20","pubTimestamp":1715653246,"startTime":"0","endTime":"0","summary":"5月14日,康希诺生物(06185)盘中上涨5.13%,截至10:20,报21.5元/股,成交1845.48万元。康希诺生物股份公司是一家专注于疫苗研发、生产和商业化的高科技生物制品企业,其主要产品包括新冠疫苗、四价流脑结合疫苗、二价流脑结合疫苗和重组埃博拉病毒病疫苗等。公司已在香港和上海两地上市,拥有全球创新的五大技术平台,已建立数十条产品研发管线,并在中国天津、上海以及墨西哥、巴基斯坦、马来西亚等国家建立了大规模现代化疫苗产业基地。截至2024年一季报,康希诺生物营业总收入1.14亿元、净利润-1.7亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/14102040634538.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435753435","title":"康希诺生物(06185)股价上升5.134%,现价港币$21.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2435753435","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2435753435?lang=zh_cn&edition=full","pubTime":"2024-05-14 10:20","pubTimestamp":1715653200,"startTime":"0","endTime":"0","summary":"[上升股]康希诺生物(06185) 股价在上午10:20比前收市价上升5.134%,现股价为港币$21.5。至目前为止,今日最高价为$21.5,而最低价为$20.5。总成交量为86.92万股,总成交金额为港币$1.838千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2405141073/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2435153575","title":"北向资金5月13日净卖出康希诺9.94万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2435153575","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435153575?lang=zh_cn&edition=full","pubTime":"2024-05-14 09:30","pubTimestamp":1715650237,"startTime":"0","endTime":"0","summary":"5月13日,北向资金减持康希诺9.94万股连续3日减持。截止当日收盘,沪股通共持有康希诺105.67万股,占流通股0.92%。沪股通减持金额前五个股分别为中远海控、长江电力、招商轮船、紫金矿业、工业富联。康希诺近5个交易日下跌2.56%,沪股通累计增持13.99万股;近20个交易日上涨0.54%,沪股通累计增持0.67万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051409344487654c8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051409344487654c8a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435734704","title":"康希诺:在研产品管线中的早期候选产品初步应用合成生物学相关技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2435734704","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2435734704?lang=zh_cn&edition=full","pubTime":"2024-05-13 18:02","pubTimestamp":1715594557,"startTime":"0","endTime":"0","summary":"5月13日,康希诺在互动平台表示,公司在研产品管线中的早期候选产品初步应用合成生物学相关技术,未来会进一步评估相关进展及优势;PBPV作为一款全球创新疫苗,该产品的对外合作也是公司全球战略布局的重要一环,因此公司也在全球范围内寻找潜在合作方,包括拥有科研实力、资源和资金的国际知名企业等,希望能够更快地推进该产品的研发进度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051318023779275566&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051318023779275566&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435234762","title":"康希诺董秘回复: 公司已与Ocugen建立合作关系,合作项目包括OCU400,具体合作信息涉及商业机密","url":"https://stock-news.laohu8.com/highlight/detail?id=2435234762","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435234762?lang=zh_cn&edition=full","pubTime":"2024-05-13 17:51","pubTimestamp":1715593904,"startTime":"0","endTime":"0","summary":"请问贵司是否有意愿同步推进大中华地区的三期实验,康希诺董秘:尊敬的投资人您好,公司已与Ocugen建立合作关系,合作项目包括OCU400,具体合作信息涉及商业机密,敬请谅解;同时,公司一直以开放的态度,拥抱包括产品销售授权、技术转移、本地化生产、研发合作在内的多样化合作模式,以期聚焦资源分配及获得更好的经营成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131751478b00ecaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131751478b00ecaa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434056039","title":"港股异动 | 康希诺生物(06185)盘中涨超6% 瑞银称MCV4业务收入今年或增长50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434056039","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434056039?lang=zh_cn&edition=full","pubTime":"2024-05-09 14:33","pubTimestamp":1715236418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,康希诺生物盘中涨超6%,截至发稿,涨4%,报20.8港元,成交额2493.53万港元。同时预测在MCV4疫苗渗透率不断提高的推动下,康希诺的MCV4业务收入于2024年将增长50%。该行指,康希诺生物MCV4疫苗的渗透率相对较低,而且新产品发布带来丰富的催化剂,将康希诺H股的目标价定于28港元,予以\"买入\"评级。此外,康希诺生物近日公布,公司研发的冻干b型流感嗜血杆菌结合疫苗已获中国国家药品监督管理局批准,可以开展相关临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119191.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434055582","title":"康希诺一季度亏损近2亿元 销售费用占营收比例41%高于同行","url":"https://stock-news.laohu8.com/highlight/detail?id=2434055582","media":"中国网财经","top":-1,"share":"https://www.laohu8.com/m/news/2434055582?lang=zh_cn&edition=full","pubTime":"2024-05-09 13:49","pubTimestamp":1715233740,"startTime":"0","endTime":"0","summary":"中国网财经5月9日讯 日前,康希诺发布2024年一季报。期内,尽管康希诺的销售费用、管理费用、研发费用及财务费用同比增幅均有所下滑,但销售费用在营收中的占比仍高达41%。康希诺在近期的投资者关系活动上解释称,目前,公司上市的非免疫规划疫苗仅有流脑产品,前期渠道搭建的费用投入较高,销售费用率高于同行业可比公司。同时,公司也会继续加强销售效能管理,预期未来收入达到一定规模后,销售费率与同行业是可比的水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050913504787e33c62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050913504787e33c62&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434035659","title":"康希诺生物(06185)上涨5.25%,报21.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2434035659","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2434035659?lang=zh_cn&edition=full","pubTime":"2024-05-09 10:37","pubTimestamp":1715222277,"startTime":"0","endTime":"0","summary":"5月9日,康希诺生物(06185)盘中上涨5.25%,截至10:37,报21.05元/股,成交1350.71万元。康希诺生物股份公司是一家专注于疫苗研发、生产和商业化的高科技生物制品企业,其主要产品包括新冠疫苗、四价流脑结合疫苗、二价流脑结合疫苗和重组埃博拉病毒病疫苗等。公司已在香港和上海两地上市,拥有全球创新的五大技术平台,已建立数十条产品研发管线,并在中国天津、上海以及墨西哥、巴基斯坦、马来西亚等国家建立了大规模现代化疫苗产业基地。截至2024年一季报,康希诺生物营业总收入1.14亿元、净利润-1.7亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/09103740577536.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434035335","title":"康希诺生物盘中异动 快速拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434035335","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434035335?lang=zh_cn&edition=full","pubTime":"2024-05-09 10:37","pubTimestamp":1715222272,"startTime":"0","endTime":"0","summary":"2024年05月09日早盘10时37分,康希诺生物股票出现波动,股价急速上涨5.00%。截至发稿,该股报21.000港元/股,成交量65.22万股,换手率0.49%,振幅5.00%。机构评级方面,在所有6家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。康希诺生物股票所在的生物技术行业中,整体涨幅为2.10%。康希诺生物公司简介:许可项目:第三类医疗器械经营;药品生产;药品进出口;药品零售;药品批发;货物进出口;技术进出口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405091037537a58e2c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405091037537a58e2c3&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":0.0256},{"period":"1month","weight":0.2209},{"period":"3month","weight":0.2586},{"period":"6month","weight":-0.1923},{"period":"1year","weight":-0.277},{"period":"ytd","weight":-0.0637}],"compareEarnings":[{"period":"1week","weight":-0.0483},{"period":"1month","weight":0.0818},{"period":"3month","weight":0.1126},{"period":"6month","weight":0.0598},{"period":"1year","weight":-0.0074},{"period":"ytd","weight":0.0916}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.023945},{"month":2,"riseRate":0.8,"avgChangeRate":0.176312},{"month":3,"riseRate":0.2,"avgChangeRate":-0.039813},{"month":4,"riseRate":0.666667,"avgChangeRate":0.073414},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.032283},{"month":6,"riseRate":0.6,"avgChangeRate":0.056507},{"month":7,"riseRate":0.6,"avgChangeRate":0.025366},{"month":8,"riseRate":0,"avgChangeRate":-0.212187},{"month":9,"riseRate":0.6,"avgChangeRate":-0.019121},{"month":10,"riseRate":0.6,"avgChangeRate":0.097338},{"month":11,"riseRate":0.8,"avgChangeRate":0.15426},{"month":12,"riseRate":0.6,"avgChangeRate":-0.050745}],"exchange":"SEHK","name":"康希诺生物","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺生物,06185,康希诺生物股票,康希诺生物股票老虎,康希诺生物股票老虎国际,康希诺生物行情,康希诺生物股票行情,康希诺生物股价,康希诺生物股市,康希诺生物股票价格,康希诺生物股票交易,康希诺生物股票购买,康希诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}